Literature DB >> 22382383

Effects of rosuvastatin and atorvastatin on renal function: meta-analysis.

Yongxia Wu1, Yan Wang, Chuankai An, Zhe Dong, Hui Liu, Yun Zhang, Mingxiang Zhang, Fengshuang An.   

Abstract

BACKGROUND: Several clinical trials have reported inconsistent findings for the effects of rosuvastatin (RSV) and atorvastatin (ATV) on renal function. The aim of this meta-analysis was to investigate the effects of these 2 statins on glomerular filtration rate (GFR) and proteinuria respectively, and determine which is better. METHODS AND
RESULTS: PubMed, CENTRAL, Web of Knowledge, and ClinicalTrials.gov website were searched for randomized controlled trials. Eligible studies reported GFR and/or proteinuria during treatment with RSV or ATV compared with control (placebo, no statins, or usual care), or RSV compared with ATV head to head. Trials that enrolled dialysis participants and teenagers were excluded. Statistical heterogeneity was assessed using the I(2) statistic, and pooled results using the random-effects model. The standardized mean differences (SMD) and ratio of means (ROM) were measured, respectively, to analyze GFR and proteinuria. Sixteen trials with a total number of 24,278 participants were identified. Compared with control, changes in the SMD of GFR were 0.04 (95% confidence interval [CI]: 0.01-0.07) and 0.59 (95%CI: 0.12-1.06) for RSV and ATV, respectively. The ROMs of proteinuria were 0.59 (95%CI: 0.46-0.74) for RSV vs. the control group, and 1.23 (95%CI: 1.05-1.43) in the head-to-head comparison.
CONCLUSIONS: Both RSV and ATV improve GFR, and ATV seems to be more effective in reducing proteinuria. The validity and clinical significance require high-quality intensive studies with composite clinic endpoints of kidney and death.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22382383     DOI: 10.1253/circj.cj-11-1385

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  8 in total

Review 1.  The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction.

Authors:  Maryam Jabarpour; Nadereh Rashtchizadeh; Hassan Argani; Amir Ghorbanihaghjo; Masoumeh Ranjbarzadhag; Davoud Sanajou; Fatemeh Panah; Amirhesam Alirezaei
Journal:  Int Urol Nephrol       Date:  2019-10-22       Impact factor: 2.370

Review 2.  Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Authors:  Michael S Kostapanos; Christos V Rizos; Moses S Elisaf
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

3.  Dialysis search filters for PubMed, Ovid MEDLINE, and Embase databases.

Authors:  Arthur V Iansavichus; R Brian Haynes; Christopher W C Lee; Nancy L Wilczynski; Ann McKibbon; Salimah Z Shariff; Peter G Blake; Robert M Lindsay; Amit X Garg
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-23       Impact factor: 8.237

Review 4.  A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.

Authors:  Venkata M Alla; Vrinda Agrawal; Andrew DeNazareth; Syed Mohiuddin; Sudha Ravilla; Marc Rendell
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

5.  Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study.

Authors:  Adrian Vlad; Mihaela Vlad; Ligia Petrica; Sorin Ursoniu; Florica Gadalean; Roxana Popescu; Daliborca Vlad; Victor Dumitrascu; Gheorghe Gluhovschi; Cristina Gluhovschi; Silvia Velciov; Flaviu Bob; Petru Matusz; Alina Secara; Anca Simulescu; Dragos Catalin Jianu
Journal:  Ren Fail       Date:  2016-11-13       Impact factor: 2.606

Review 6.  Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes.

Authors:  Enas A Enas; Arun Kuruvila; Pravien Khanna; C S Pitchumoni; Viswanathan Mohan
Journal:  Indian J Med Res       Date:  2013-10       Impact factor: 2.375

Review 7.  The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in renal disease.

Authors:  Sabas I Gomez; Christos G Mihos; Andres M Pineda; Orlando Santana
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-03-28

Review 8.  Overcoming Challenges With Statin Therapy.

Authors:  J David Spence; George K Dresser
Journal:  J Am Heart Assoc       Date:  2016-01-27       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.